(Q37103609)

18 August 2017

1 reference

title

Experimental non-ATP-competitive therapies for chronic myelogenous leukemia (English)

1 reference

18 August 2017

1 reference

A Quintás-Cardama

1

1 reference

18 August 2017

publication date

6 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

22

1 reference

18 August 2017

issue

5

1 reference

18 August 2017

page(s)

932-940

1 reference

Molecular mechanisms of action of antisense drugs

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

Antisense properties of peptide nucleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Minimal residual disease in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

A myristoyl/phosphotyrosine switch regulates c-Abl

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

https://api.crossref.org/works/10.1038%2FLEU.2008.47

1 reference

7 January 2021

Ancient pathways programmed by small RNAs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Role for a bidentate ribonuclease in the initiation step of RNA interference

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Specific inhibition of bcr-abl gene expression by small interfering RNA.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimics.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Targeting lentiviral vectors to specific cell types in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

New non-viral method for gene transfer into primary cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Approaches for the sequence-specific knockdown of mRNA.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Inhibiting transcription of chromosomal DNA with antigene peptide nucleic acids.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Antiproliferative effect in chronic myeloid leukaemia cells by antisense peptide nucleic acids

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Chronic myeloid leukemia as an immunological target

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Allogeneic stem cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Critical role for Gab2 in transformation by BCR/ABL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Negative regulation of p120GAP GTPase promoting activity by p210bcr/abl: implication for RAS-dependent Philadelphia chromosome positive cell growth

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

RAS and leukemia: from basic mechanisms to gene-directed therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Ras as a therapeutic target in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

The inhibition of ERK/MAPK not the activation of JNK/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Rac GTPases differentially integrate signals regulating hematopoietic stem cell localization

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Histone modifications: signalling receptors and potential elements of a heritable epigenetic code

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Oral fingolimod (FTY720) for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Chronic myeloid leukaemia as a model of disease evolution in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.47

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.47

1 reference

Dimensions Publication ID

18 August 2017

1013184411

0 references

1 reference